VarmX is a spin-off of the Leiden University Medical Center. VarmX is a company that has the mission to develop and manufacture therapeutic proteins in order to restore hemostasis. VarmX focuses on the development of therapies in the areas of hemostasis and thrombosis. The company develops therapeutic drugs that have been designed to restore blood clotting in bleeding patients.
The company's drugs are modified recombinant human coagulation factor which are capable of restoring blood clotting in the presence of direct factor anticoagulants such as rivaroxaban, apixaban and edoxaban, enabling physicians to safely and effectively restore hemostasis in case of bleeding.
VarmX’s lead compound, VMX-COO1, is developed to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The drug contains modified natural coagulation factor that can instantly and efficiently restore blood clotting in patients taking anticoagulants.
